OrthoPediatrics (NASDAQ:KIDS) Stock Gets Price Target Boost from Truist Financial

OrthoPediatrics (NASDAQ:KIDS) had its price target hoisted by equities researchers at Truist Financial from $22.00 to $28.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial‘s price target would suggest a potential downside of 7.82% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on KIDS. Lake Street Capital reissued a “buy” rating and set a $38.00 price objective on shares of OrthoPediatrics in a research note on Wednesday. BTIG Research raised their price objective on OrthoPediatrics from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday. Stifel Nicolaus lifted their target price on OrthoPediatrics from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 target price on shares of OrthoPediatrics in a report on Wednesday. Finally, Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.75.

OrthoPediatrics Price Performance

OrthoPediatrics stock traded up $6.56 during mid-day trading on Wednesday, reaching $30.38. 588,454 shares of the company’s stock traded hands, compared to its average volume of 183,278. OrthoPediatrics has a 12-month low of $14.42 and a 12-month high of $29.78. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average of $23.02 and a two-hundred day moving average of $19.41. The company has a market cap of $793.14 million, a price-to-earnings ratio of -18.14 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The business had revenue of $72.66 million during the quarter, compared to the consensus estimate of $68.50 million. Equities analysts forecast that OrthoPediatrics will post -1.14 earnings per share for the current year.

Insider Buying and Selling at OrthoPediatrics

In other news, major shareholder Jennifer Pritzker sold 326,700 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Squadron Capital Llc sold 326,700 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total value of $7,527,168.00. Following the completion of the sale, the insider owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,100,000 shares of company stock worth $46,747,931 over the last 90 days. Company insiders own 32.50% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in OrthoPediatrics in the second quarter worth $24,347,000. Granahan Investment Management LLC grew its holdings in shares of OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after purchasing an additional 232,760 shares during the last quarter. Wasatch Advisors LP increased its stake in OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after buying an additional 186,357 shares during the period. Roubaix Capital LLC increased its stake in OrthoPediatrics by 23.8% in the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company’s stock worth $4,603,000 after buying an additional 55,724 shares during the period. Finally, AIGH Capital Management LLC bought a new stake in OrthoPediatrics during the 2nd quarter valued at about $5,161,000. Institutional investors own 69.05% of the company’s stock.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Record revenue and raised guidance: Third-quarter revenue reached $72.7 million, up 19% year over year and ahead of analysts’ approximately $68.5 million estimate. Management raised 2026 revenue guidance to $270 million-$273 million, signaling continued demand for the company’s pediatric orthopedic products. OrthoPediatrics third-quarter results and guidance
• Positive Sentiment: New product approval expands growth opportunities: The FDA granted 510(k) clearance for the PNP Femur Retrograde Nail System, expanding OrthoPediatrics’ Pediatric Nailing Platform for femoral trauma and deformity correction. The company also completed its first implantations, providing an early commercial milestone. FDA clearance and first implantations
• Positive Sentiment: Investor confidence improved after the earnings call: Management highlighted the record quarterly performance and raised outlook, reinforcing the company’s growth narrative and helping explain the increased trading activity. Q3 2026 earnings call highlights
• Neutral Sentiment: Losses remain a consideration: OrthoPediatrics reported a quarterly loss of $0.23 per share. This was better than one published consensus estimate of a $0.25 loss, but below another estimate of a $0.21 loss, making the earnings result mixed rather than a clear bottom-line beat. OrthoPediatrics Q3 earnings analysis

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.